CD79a Antibody, anti-human, REAfinity™
Synonyms: Igα, MB-1
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
1 Citation
Clone:
REA1168 | HM47
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC, MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD79a Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
PE-Vio 615
PE-Vio 770
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-120-934, 130-120-940
Description:
Human peripheral blood mononuclear cells (PBMCs) were fixed and permeabilized followed by intracellular staining with CD79a antibodies or with the corresponding REA Control (I) antibodies (left images) as well as with CD19 antibodies. Flow cytometry was performed using the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-120-934, 130-120-940
Testing grade:
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin-embedded (FFPE) tonsil section. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using CD79a APC (green) and CD3 PE (red) for 10 minutes at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application image
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-120-934, 130-120-940
Testing grade:
Extended validation for CD79a Antibody, anti-human, REAfinity™
Specificity
Other clones
Overlap in epitope recognition with REA1168
HM47
high

Cells were incubated with an excess of purified unconjugated CD79a (REA1168) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Specifications for CD79a Antibody, anti-human, REAfinity™
Overview

Clone REA1168 regognizes the cytoplamic domain of CD79a, which is also known as MB-1 and Igα. Along with CD79b (Igβ), CD79a is associated with surface Ig (sIg) to form the B cell antigen receptor complex. CD79a is a 47 kDa glycoprotein and comprises a single extracellular immunoglobulin domain, a transmembrane domain, and a signaling intracellular domain with immunoreceptor tyrosine-based activation motif (ITAM). CD79a/CD79b heterodimer facilitates differentiation of pre–B cells from pro–B cells, surface expression of sIg, signal transduction following antigen recognition, and enodocytosis of recognised antigens. Surface expression of CD79a dimishes in plasma cells, where it is mainly found as an intracellular molecule. CD79 is considered a B cell–specific marker and is often used to identify the B cell lineage of acute lymphoblastic leukemia. Recent reports however suggest expression of CD79a in T cell acute lymphoblastic leukemia. Individuals lacking CD79a have low/absent circulating pre–B cells and serum antibodies due to a block in B cell development.

Additional information: Clone REA1168 displays negligible binding to Fc receptors.

Alternative names

Igα, MB-1

Detailed product information

Technical specifications

Clone
REA1168
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human, mouse, non-human primate
Cross-reactivity
chimpanzee (Pan troglodytes), olive baboon (Papio anubis), mouse
Antigen
CD79a
Molecular mass of antigen [kDa]
22
Distribution of antigen
plasma cells, plasma B cells, leukemia cells
Entrez Gene ID
RRID
AB_2784279, AB_2784277, AB_2784278, AB_2784283, AB_2784280, AB_2784284, AB_2784281, AB_2784282

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD79a Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support